Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function

Abstract excerpt

BACKGROUND: The success of chimeric antigen receptor (CAR) T cell therapy for hematological malignancies has not yet translated into long-term elimination of solid tumors indicating the need for adequately tuning CAR T cell functionality. METHODS: We leveraged a translational pipeline including biophysical characterization and structural prediction of the CAR binding moiety, evaluation of cellular avidity,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to vaccines and immunoinformatics approaches